WEP Clinical Ltd (WEP), a specialist services company that works with drug developers to help patients and physicians gain early access to medicines, is pleased to announce the execution of a Master Services Agreement (MSA) with Australian biotech, Medlab Clinical Ltd (Medlab), for the exclusive development and delivery of Named Patient Programmes relating to the unlicensed supply of Medlab’s proprietary NanaBisTM and NanoCBDTM to patients in the UK and Europe.

The MSA with WEP is the first partnership for Medlab to supply their cannabinoid medications outside of its current Australian Special Access Scheme. Over the next 3 months, WEP and Medlab will undertake the required work to prepare for the entry of both NanaBis™ and NanoCBD™ into the UK.

Jas Khera, Managing Director of WEP Clinical, said:

“WEP Clinical is pleased to partner with Medlab Clinical to bring novel cannabinoid medications to patients in Europe and UK. The early clinical trial data and development programme supporting their products in cancer pain management coupled with their unique patented NanoCelle® delivery platform is what excites us about working exclusively with Medlab in the cannabis-based medicine space.”

About WEP Clinical

Established in 2008, WEP Clinical is a specialist services company that works with drug developers to help patients and physicians gain early access to medicines when no other treatment options are available. We have offices located in London, United Kingdom; RTP North Carolina, United States; Lisbon, Portugal; and Dublin, Ireland and possess all the necessary licenses allowing us to meet drug access and distribution needs across all regions, worldwide. We are passionate about helping those in need. For more information, please visit www.wepclinical.com.

About Medlab Clinical 

Medlab Clinical LTD (ASX:MDC) is pioneering the development and Commercialisation of a delivery platform, allowing for enhanced medical properties, including increased efficacy, safety, patient compliance and stability. Medlab’s pipeline comprises a number of small and large molecules from repurposing generic medicines to enhancing the delivery of immunotherapies. Patented lead drug candidate NanaBis™ has been developed for cancer bone pain as a viable alternative to opioid use. Data to date, strongly suggests NanaBis™ may be equally effective in non-cancer neuropathic pain. NanoCelle®, the patented delivery platform is wholly owned by Medlab and developed in Medlab’s owned OGTR Registered Laboratory. NanoCelle® is designed to address known medication problems, addressing global unmet medical needs. Medlab operates in Australia (Head Office), USA, and the UK.
For more information, please visit www.medlab.co